HRS9950 / Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
HRS9950 / Jiangsu Hengrui Pharma
NCT05905458: A Phase II Clinical Study of the Efficacy and Safety of HRS9950 Tablets in Chronic Hepatitis B Patients Who Are Virologically Suppressed on Nucleoside or Nucleotide Analogues (NAs)

Completed
2
54
RoW
HRS9950 tablets, HRS9950 placebo tablets
Chengdu Suncadia Medicine Co., Ltd.
Chronic Hepatitis B
11/24
11/24
NCT04464733: Safety, Tolerability, Pharmacokinetics(PK), Pharmacodynamics(PD) and Food Effect of HRS9950 in Healthy and CHB Subjects

Completed
1
146
RoW
HRS9950, Placebo
Jiangsu HengRui Medicine Co., Ltd.
Chronic Hepatitis b
05/23
05/23
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
HRS9950 / Jiangsu Hengrui Pharma
NCT05905458: A Phase II Clinical Study of the Efficacy and Safety of HRS9950 Tablets in Chronic Hepatitis B Patients Who Are Virologically Suppressed on Nucleoside or Nucleotide Analogues (NAs)

Completed
2
54
RoW
HRS9950 tablets, HRS9950 placebo tablets
Chengdu Suncadia Medicine Co., Ltd.
Chronic Hepatitis B
11/24
11/24
NCT04464733: Safety, Tolerability, Pharmacokinetics(PK), Pharmacodynamics(PD) and Food Effect of HRS9950 in Healthy and CHB Subjects

Completed
1
146
RoW
HRS9950, Placebo
Jiangsu HengRui Medicine Co., Ltd.
Chronic Hepatitis b
05/23
05/23

Download Options